Consecutive case series of 244 age-related macular degeneration patients undergoing implantation with an extended macular vision IOL

Qureshi, Muhammad Arshad; Robbie, Scott; Hengerer, Fritz H.; Conrad-Hengerer, Ina; Artal, Pablo

doi:10.5301/ejo.5001052

Cited by 14 publications

(13 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There are a few reports on the use of dual optic system using two IOLs to create an intraocular Galilean telescopic system,13 14 and recently there has been one report on the use of wavefront-optimised IOL (iolAMD Eyemax mono) to provide enhanced quality of vision during cataract surgery in patients with AMD. However, it is unclear how the optics of this IOL works 15…”

Section: Discussionmentioning

confidence: 99%

“…Although this device could be implanted through a small, self-sealing incision it had the same drawbacks of having a telescopic optics inside the eye causing severe restriction to the field of vision. Recently, there has been a report on the use of wavefront optimised IOL to provide enhanced quality of image on the macula during cataract surgery in patients with AMD 15. The Scharioth macula lens (SML) (A45 SML, Medicontur, Hungary) is a single-piece hydrophilic IOL implanted monocularly in the ciliary sulcus as a supplementary/piggyback IOL in pseudophakic eyes with AMD.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial

Srinivasan

2019

BMJ Open Ophth

View full text Add to dashboard Cite

ObjectiveTo report the visual and refractive outcomes following monocular implantation of a supplementary (piggyback) Scharioth macula lens (SML) in previously pseudophakic eyes with age-related macular degeneration (AMD).Methods and analysisProspective European multicentre clinical trial. 50 eyes of 50 pseudophakic patients with either dry or previously treated and stable neovascular AMD for at least 6 months were included. The inclusion criteria were age over 55, corrected distance visual acuity (CDVA) of 0.4–0.1 (decimal), improvement of at least three lines of corrected near visual acuity (CNVA) when tested with a +6.0 dioptre (D) reading addition at 15 cm, compared with a +2.5 D reading addition at 40 cm using a standardised, self-illuminated Early Treatment Diabetic Retinopathy Study near vision chart. The SML intraocular lens (IOL) was implanted as an add-on/piggyback IOL in the ciliary sulcus, monocularly in the better seeing eye of each subject meeting the inclusion criteria.ResultsThere were no intraoperative complications. One subject had the SML explanted in the postoperative period due to postoperative glare/halos. The mean CNVA improved from 0.23±0.12 (decimal) preoperatively to 0.57±0.33 at 1 year. The mean CDVA remained unchanged measuring 0.19±0.13 preoperatively and 0.19±0.09 at 1 year postoperatively.ConclusionThe SML appears to be safe and effective in improving the CNVA in patients with AMD. Data suggest that the CDVA remains unaffected following implantation. Further data are needed to assess the long-term safety and efficacy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial

Srinivasan

2019

BMJ Open Ophth

View full text Add to dashboard Cite

show abstract

“…There were no intraoperative or postoperative complications related to the IOL in our series, which is a foldable lens implanted in a routine approach with a universal injector through a 2.2-mm or larger clear cornea incision [ 11 ]. Similarly, Qureshi et al [ 4 ] reported favorable safety and visual acuity improvement in a study of another injectable AMD IOL. Not only is the LENTIS® MAX LS-313 MF 80 IOL an injectable lens, but it is built on the same platform as several existing presbyopia-correcting IOLs (LENTIS® Mplus MF 20 and MF 30, LENTIS® Comfort, OSD Medical, Germany).…”

Section: Discussionmentioning

confidence: 88%

“…Vision impairment in eyes with advanced dry AMD is characterized by central scotoma that interferes with the ability to recognize faces, read, drive a car, and complete numerous other routine daily activities that are essential for independent living [3]. Although magnifying aids and vision rehabilitation techniques that train patients to utilize the intact peripheral retina can help individuals cope with their central vision loss, these strategies suffer drawbacks that make them less than ideal [4].…”

Section: Introductionmentioning

confidence: 99%

Four Years of Observation to Evaluate Autonomy and Quality of Life after Implantation of a High-Add Intraocular Lens in Age-Related Macular Degeneration Patients

Borkenstein

2020

Case Rep Ophthalmol

View full text Add to dashboard Cite

Visual impairment resulting from advanced dry age-related macular degeneration (AMD) limits the ability to perform activities required for independent living and adversely affects quality of life. We aimed to determine changes in these parameters in patients with AMD-related geographic atrophy who underwent magnifying cataract surgery (MAGS) using a foldable, bifocal high-add intraocular lens (IOL). The high-add IOL (LENTIS ® MAX LS-313 MF 80, Oculentis) was implanted in the better seeing or dominant eye of eligible patients with clinically significant cataract, best corrected distance visual acuity 1.3-0.5 logMAR (20/400-20/63), best corrected near visual acuity >0.8 logMAR (20/125), and stable advanced dry AMD. Self-reported feasibility of performing routine activities and change in quality of life were the main outcome

show abstract

“…Data are now emerging for EyeMax Mono, a new single-piece, soft, hydrophobic, acrylic IOL that increases breadth of focus and reduces blur, thereby improving image quality across all areas of the macula and not just the foveal center. [6,7] The lens optics are wavefront-optimized to provide an enhanced quality of image to an area extending 10° from the foveal center, and laboratory simulations indicate that the lens delivers superior image quality compared with standard monofocal IOLs at 4° and 7.5° of retinal eccentricity. [6]…”

Section: Introductionmentioning

confidence: 99%

A case report detailing use of a new intraocular lens with advanced technology, designed specifically for patients with center-involving macular disorders

Borkenstein

Borkenstein²

2019

Medicine

View full text Add to dashboard Cite

Rationale: Many studies have shown that cataract surgery can be performed safely and improve visual acuity, without increasing the risk of progression of existing age-related macular degeneration (AMD). Data are emerging for an intraocular lens (IOL) that utilizes an advanced optical design to optimize the image supplied to all areas of the macula and not just the foveal center, which may benefit patients with center-involving macular disorders. Patient concerns: An 83-year-old Caucasian female presented with poor contrast sensitivity and color perception with increasing glare over the preceding year. Diagnosis: She had a progressive cortical cataract and stable dry AMD in the left eye, and wet AMD in the right eye. In the left eye, preoperative best-corrected distance visual acuity (BCDVA) was 0.2 (decimal) and best-corrected near visual acuity (BCNVA) was 0.05 (decimal). Interventions: Standard small-incision phacoemulsification was performed in the left eye, with capsular bag implantation of EyeMax Mono (LEH Pharma, London, UK), a single-piece, soft, hydrophobic, acrylic IOL designed to optimize image quality across the macula, rather than a standard monofocal lens. Outcomes: At 6 months postoperation, visual acuity in the left eye had markedly improved, with a BCDVA of 0.5 (decimal) and a BCNVA of 0.2 (decimal). Conclusion: In this first case undertaken at our center (and the first in Austria), cataract extraction and EyeMax Mono implantation were performed safely, with good subjective and objective outcome measures consistent with the effects of image optimization across the macula. Further studies of this IOL in patients with center-involving macular disorders, such as AMD, are warranted.

show abstract

Consecutive case series of 244 age-related macular degeneration patients undergoing implantation with an extended macular vision IOL

Abstract: This novel IOL appears safe in the short to medium term. Improvements in postoperative CDVA and CNVA exceed those observed with standard implants.

Cited by 14 publications

References 29 publications

Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial

Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial

Four Years of Observation to Evaluate Autonomy and Quality of Life after Implantation of a High-Add Intraocular Lens in Age-Related Macular Degeneration Patients

A case report detailing use of a new intraocular lens with advanced technology, designed specifically for patients with center-involving macular disorders

Contact Info

Product

Resources

About